The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
暂无分享,去创建一个
D. Venzon | B. Wood | T. Greten | C. Sanders | D. Kleiner | W. Figg | C. Xie | F. Korangy | E. Yusko | A. Duffy | J. Rytlewski | G. Brar | D. Pratt | Mei ElGindi | M. Sandhu | David Agdashian | D. Agdashian
[1] M. Kudo,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.
[2] M. Kudo,et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. , 2018 .
[3] M. Esteller,et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. , 2017, Gastroenterology.
[4] P. Galle,et al. Immune oncology in hepatocellular carcinoma—hype and hope , 2017, The Lancet.
[5] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[6] M. Vignali,et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis , 2017, PLoS medicine.
[7] S. Steinberg,et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. , 2017, Journal of hepatology.
[8] T. Greten,et al. Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma , 2017, Nature Reviews Gastroenterology &Hepatology.
[9] T. Greten,et al. Targets for immunotherapy of liver cancer. , 2017, Journal of hepatology.
[10] J. Becker,et al. T cell receptor repertoire usage in cancer as a surrogate marker for immune responses , 2017, Seminars in Immunopathology.
[11] H. Kohrt,et al. Biomarkers associated with checkpoint inhibitors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] P. Hegde,et al. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.
[13] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[14] Antoni Ribas,et al. Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.
[15] Ryan Emerson,et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.
[16] T. Greten,et al. Hepatocellular Carcinoma from an Immunologic Perspective , 2013, Clinical Cancer Research.
[17] T. Greten,et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies , 2013, Cancer Immunology, Immunotherapy.
[18] R. Nussenblatt,et al. Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.
[19] C. Desmarais,et al. Ultra-sensitive detection of rare T cell clones. , 2012, Journal of immunological methods.
[20] Abigail Wacher,et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. , 2009, Blood.